FLU-IGIV

N/A

Report date: 2024/06/17 20:00:40

Base Information

Drug NameFLU-IGIV
Drug Alias NameInfluenza immune globulinFLU IGIVAnti-influenza immune globulin intravenous (Human)Intravenous hyperimmune immunoglobulinNP-025
ClassificationBiologics > Protein drugs > ImmunoglobulinBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsInfluenza A virus infectionsInfluenza B virus infection
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPuerto Rico +[7] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEmergent Biosolutions Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEmergent Biosolutions IncNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsN/A
Inactive IndicationsInfluenza A virus infectionsInfluenza B virus infection

Other Information

ATC CodeN/A
Related LinksN/A